Low risk of elevated IOP with lampalizumab for geographic atrophy over 1 year

Retrieved on: 2024-07-02 17:53:17

Tags for this article:

Monoclonal antibodies

Ophthalmology

Angiogenesis inhibitors

Eye surgery

Intravitreal administration

Ophthalmic drug administration

Macular degeneration

Intravitreal injection

Click the tags to see associated articles and topics

Low risk of elevated IOP with lampalizumab for geographic atrophy over 1 year. View article details on hiswai:

Excerpt

References: 4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy. Press Release; June ...

Article found on: www.ophthalmologytimes.com

View Original Article